Low-Intensity Shockwave Therapy (LI-ESWT) in Diabetic Kidney Disease: Results from an Open-Label Interventional Clinical Trial.

PURPOSE: Treatment with low-intensity shockwave therapy (LI-ESWT) is associated with angiogenesis and is suggested as a treatment for different types of vascular diseases. It was hypothesized that LI-ESWT improves the renal filtration barrier and halts the progression of GFR decline in diabetic kidney disease (DKD) potentially through VEGF and NO formation. We present the first data on LI-ESWT in human DKD.
METHODS: The study was designed as an interventional, prospective, one-arm, Phase 1 study. We investigated change in GFR and albuminuria in 28 patients with DKD treated with six sessions of LI-ESWT over three weeks. The patients were followed for six months. Urine excretion of kidney injury markers, vascular endothelial growth factor (VEGF) and nitric oxide metabolites (NOx) was studied after LI-ESWT.
RESULTS: There were no significant changes in GFR and albuminuria up to six months after LI-ESWT compared to baseline. Urine VEGF was transiently reduced one month after LI-ESWT, but there were no other significant changes in urine VEGF or NOx after LI-ESWT. Secondary analysis showed that NOx increased after LI-ESWT in patients who had low levels of NOx at baseline. Kidney injury marker trefoil factor 3 (TFF3) increased acutely after the first session of LI-ESWT indicating transient endothelial repair. Other markers of kidney injury were stable in relation to LI-ESWT.
CONCLUSION: LI-ESWT treatment did not significantly improve kidney function and albumin excretion. It is concluded that LI-ESWT is not harmful. A randomized blinded study should be performed to clarify whether adjunctive treatment with LI-ESWT is superior to standard treatment of DKD.

Introduction

Diabetes mellitus (DM) affect 493 million adult individuals worldwide1 and is associated with a number of complications reducing the life-span and quality of life of patients living with DM.2 One of the most serious and devastating complications of DM is the presence of diabetic kidney disease (DKD) which may ultimately lead to end-stage kidney disease and considerably increased risk of death. DKD is estimated to affect 20–40% of all patients with DM3 with increasing prevalence found in older patients. Thus, more than 50% of patients with DM aged >65 years might be affected by DKD.4

We recently proposed low-intensity shockwave therapy (LI-ESWT) as a new reno-protective intervention to reduce the progression of DKD. LI-ESWT is applied with approximately 10% of the energy level that is used in the setting of lithotripsy (ESWL). LI-ESWT can be applied to different organs exposed to ischemia in order to induce angiogenesis via upregulation of local vascular endothelial growth factor (VEGF) and nitric oxide (NO) production.5–7 Other potential beneficial effects associated with LI-ESWT include attraction of stem cells8,9 and reduction of fibrosis10,11 in target organs. Clinically, LI-ESWT reduces symptoms in ischemic heart disease12 and peripheral arterial disease.13 Furthermore, LI-ESWT improves the healing of diabetic foot ulcers14 and was recently recommended for vasculogenic erectile dysfunction.15

LI-ESWT is a type of acoustic wave characterized by a high peak positive pressure followed by a slightly negative, tensile pressure that causes shear stress of the cell membrane, cytoskeleton, and extracellular matrix components.16,17 The application of LI-ESWT leads to activation of different intracellular signaling pathways involved in endothelial cell proliferation and angiogenesis by stimulation of specific cell membrane receptor proteins18,19 and cell membrane poration.20 LI-ESWT can affect tissue fibrosis and inflammation through a suppression of TGF-beta release,21 NF-kappa-beta pathway,22 and interleukins 1 and 623 leading to decreased infiltration of fibrocytes,10 leukocytes,24 and inflammatory macrophages.23

The findings that LI-ESWT may suppress inflammation and fibrosis and promote regeneration in vascular diseases motivated the hypothesis that LI-ESWT alleviates the microvascular complications associated with DKD ie, reduced GFR and albuminuria. To test the hypothesis, a protocol with six interventions over a period of three weeks was performed on 28 patients with DKD. The patients were followed for six months.

We previously reported preliminary data demonstrating the clinical safety of LI-ESWT in a subset of the cohort of patients with DKD.25 The present study reports the full set of data after completing the trial with six-month follow-up on all included patients. The effect of LI-ESWT treatment on glomerular filtration rate (GFR), albuminuria, VEGF and NO excretion, blood pressure, and kidney injury markers is shown in the full cohort of patients with DKD.

Patients and Methods

The study was designed as a one-arm, prospective, interventional cohort study. We recruited 28 patients with diabetic kidney disease between May 27th, 2015 and June 27th, 2019 at Odense University Hospital, Odense, Denmark. The inclusion and exclusion criteria for the study are presented in Box 1. Patients received treatment with Li-ESWT and were followed up at one month, three months, and six months after the last treatment session with LI-ESWT. An overview of study investigations is provided in Figure 1.

Box 1

Inclusion and Exclusion Criteria

Inclusion

Patients with DM and stage 3 CKD

Exclusion

Non-DM kidney diseasea

Kidney or ureteral stone

Obstructive uropathy

Untreated urinary tract infection

Kidney tumorb

Anticoagulant medical therapyc

Bleeding disorder

Pregnancy

Office blood pressure >140/90 mmHg

Abnormal renogrammed

Single kidney

Kidney transplant

AMI within one year

Severe psychiatric disease

Notes: aPatients where non-DM kidney disease was suspected from medical history or clinical evaluation. bPatients with simple renal cortical cysts (Bosniak class I and II) were allowed to participate. cPatients receiving platelet inhibitors were allowed to participate. d<30% function on one kidney

Figure 1

Overview of investigations.

Preliminary results from the present trial were published in a safety report.25 In the present analysis, the results were reported for a total of 28 patients. Only 14 patients were included in our preliminary safety report.

Li-ESWT

Six treatment sessions with LI-ESWT were carried out over a period of three weeks. There were three to four days interval between each of the treatment sessions. The treatment was carried out using a Modulith SLX-2 device (Storz Medical, Tägerwilen, Switzerland). At every session, each kidney was treated with 1000 shocks at the upper pole, 1000 shocks at the middle part, and 1000 shocks at the lower pole. The energy level was increased stepwise at every part of the kidney within the first 200 shocks; we started at minimum energy setting at 0.1 (0.136 mJ/mm2) and gradually increased up to energy setting 0.7 (0.265 mJ/mm2). The remaining 800 shock at each part of the kidney were applied with energy setting 0.7. All shocks were applied with extended focal size and 4 Hz frequency. The patients were placed on their back or side during the treatments. We used water as coupling medium between the device and the patients’ skin. The kidneys were localized in-line with ultrasound.

Outcomes

GFR was determined with 51-chromium-EDTA or Tc-99m-DTPA clearance method. Albuminuria was quantified in 24-hour urine collection samples. We measured ambulatory blood pressure using an Ambulatory Blood Pressure Monitor model 90217A (Spacelabs Healthcare, USA) with blood pressure readings every 20 minutes during daytime from 6 am to 10 pm and every 60 minutes during the nighttime. Blood samples were drawn from a peripheral vein. Concise methods for these outcomes were previously described.25

Spot Urine Samples

Nitric oxide metabolites (NOx), VEGF and kidney injury markers were measured in spot urine samples taken at baseline, at 1st and 6th treatment sessions, and at follow-up after 1, 3, and 6 months. At the 1st treatment session, the spot urine sample was taken immediately after LI-ESWT to assess the acute effects of the treatment. At the 6th treatment session, the spot urine sample was taken before LI-ESWT to assess the subacute effects of the previous treatment which was conducted 3–4 days earlier.

The concentrations of VEGF and kidney injury markers calbindin, clusterin, kidney injury molecule-1 (KIM-1), osteoactivin, and trefoil factor 3 (TFF3) were determined in spot urine samples with a commercially available multiplex ELISA assay (Kidney Injury Panel 3 Human Kit, Meso Scale Diagnostics, Rockville, Maryland, USA). Nitric oxide metabolites nitrite and nitrate (NOx) were quantified in spot urine samples using a commercial colorimetric assay (Nitrate/Nitrite Colorimetric assay Kit, Cayman Chemical, Ann Arbor, Michigan, USA).

The concentrations of the analytes were determined in duplicate and normalized to creatinine concentration.

Statistics

Non-parametric Friedman test with level of significance 0.05 was used for GFR, albuminuria, ambulatory blood pressure, and plasma variables. Unadjusted post-hoc test was carried out for significant outcomes of the Friedman test. We excluded six patients with non-significant excretion of albumin in urine (<30 mg/24-hours through all study visits) from the analysis of albuminuria. Levels of NOx, VEGF, and kidney injury markers were compared to baseline with Wilcoxon signed rank test with significance level set to 0.10 in order to prevent from type II errors evaluating the safety of LI-ESWT.

We performed an exploratory analysis of correlations between the variables obtained at baseline, treatment sessions, and follow-up. Linear correlations between continuous variables were tested using Pearson’s product-moment correlation. Non-linear correlations between continuous variables were tested using Spearman’s rank-order correlation.

All statistics were performed in SPSS Statistics version 26 for Mac (IBM, Armonk, NY, USA).

Results

Twenty-eight included patients completed the treatments with LI-ESWT as per protocol. One patient dropped out of the study after a three-month follow-up visit. All other patients completed the follow-up program and study investigations. There were twenty male patients and eight female patients (Table 1). The patients had a median age of 61 years (IQR 54; 69) and were diagnosed with type 2 DM (n=19), type 1 DM (n=6), latent autoimmune diabetes in adults (LADA) (n=2), or maturity onset diabetes of the young type 3 (MODY3) (n=1). The median duration of DM was 25 years (IQR 13; 35).

Table 1

Baseline Demographics

Sex
Male	20 (71%)
Female	8 (29%)
Age (years)	61 (54; 69)
Body mass index (kg/m2)	28 (22; 32)
Smoking
Current	3 (11%)
Former	15 (54%)
Never	10 (36%)
Package years, none-smokers excluded	18 (7; 41)
Alcohol consumption (12g/week)	1 (0; 5)
Diabetes mellitus
Type 1	6 (21%)
Type 2	19 (68%)
Other (MODY/LADA)	3 (11%)
Duration of diabetes (years)	25 (13; 35)
Medical treatment of diabetes mellitus
None	1 (4%)
Metformin	7 (25%)
Insulin	23 (82%)
Sulfunylurea	2 (7%)
DPP-4 inh./GLP-1-RA/SGLT2-inh.	7 (25%)
Medical treatment of hypertension
None	3 (11%)
ACE-inhibitor /AT2-antagonist	23 (82%)
Thiazide	14 (50%)
Furosemide	12 (43%)
Beta-blocker	8 (29%)
Calcium-antagonist	15 (54%)
Other	9 (32%)
Receiving lipid-lowering medication	25 (89%)
Charlson Index scorea
2	12 (43%)
3–4	13 (46%)
5 or more	3 (11%)

Notes: Data are number (%) or median (25% quartile ; 75% quartile). aMinimum Charlson Index Score is 2 according to the diagnosis of diabetic nephropathy in all patients.

Clinical Safety

A mild degree of macroscopic hematuria was observed after the treatment with LI-ESWT in six of the patients but was not associated with significant adverse renal outcomes. Macroscopic hematuria was only present in the patients’ first urine after the treatments and was dissolved at their next void. Microscopic hematuria was observed in six patients (excluding the patients who had macroscopic hematuria) after the treatments. In general, the patients experienced transient mild to moderate flank tenderness lasting two to three days after the treatments with LI-ESWT. All of the patients reported that flank tenderness was reduced before a new treatment session was initiated and did not increase from time to time through the treatments. Ultrasound scans performed one and three months after LI-ESWT showed no hematoma in the kidneys.

Functional Outcomes

There were no significant changes in the patients’ GFR and albuminuria after LI-ESWT (Table 3). At baseline, median GFR was 37.0 mL/min/1.73m2 (IQR 27.3; 49.0) compared to 36.0 mL/min/1.73m2 (IQR 27.0; 46.8) at three-month follow-up and 37.0 mL/min/1.73m2 (IQR 24.0; 51.0) at six-month follow-up (p=0.351). Median urinary albumin excretion was 302 mg/24-hours (IQR 78; 786) at baseline, 253 mg/24-hours (IQR 80; 1187) at one-month follow-up, 295 mg/hours (58; 907) at three-month follow-up, and 214 mg/hours (100; 987) at six-month follow-up (p=0.801). Individual curves representing GFR and albuminuria in each patient during the study are provided in Figure 2.

Table 3

Molecular Markers

		Baseline	1. Treatment	6. Treatment	1 Month	3 Months	6 Months
NOx	µg/mmol	8.9 (5.3; 19.2)	12.6 (7.5; 20.2)	10.6 (8.0; 18.8)	11.7 (7.1; 22.8)	13.1 (5.4; 17.7)	10.5 (5.4; 23.2)
VEGF	ng/mmol	76.0 (36.3; 123.1)	66.6 (32.8; 99.4)	72.2 (45.8; 138.8)	54.9 (39.5; 101.7)a	56.8 (32.9; 120.0)	56.0 (34.8; 140.3)
KIM-1	ng/mmol	394 (62.2; 1150)	69.8 (47.0; 120.7)	375 (78.7; 1257)	431 (57.7; 1346)	549 (69.3; 1336)	190 (76.2; 1004)
Calbindin	ng/mmol	367 (286; 760	412 (230; 726)	361 (297; 664)	357 (275; 595)	388 (228; 613)	351 (242; 490)
Clusterin	ng/mmol	8137 (3131; 23,486)	4699 (2780; 17,732)	7630 (3513; 32,508)	6858 (2936; 18,462)	6706 (3491; 26,896)	5155 (2798; 16,876)
Osteoactivin	ng/mmol	407 (225; 1094)	750 (434; 1273)	404 (279; 972)	351 (215; 895)	370 (159; 550)	451 (212; 1128)
TFF3	ng/mmol	13.3 (8.6; 33.7)	23.1 (12.2; 66.5)b	13.2 (6.9; 34.2)	9.9 (5.3; 32.6)	7.3 (2.0; 40.2)	12.7 (5.3; 26.0)

Notes: Data are shown as median (IQR). The concentrations of the markers were normalized to creatinine concentration (mmol/l). All follow-up values were compared to baseline using related-samples Wilcoxon signed rank test. Significance level was set at p<0.10. Significant results are tagged and highlighted in bold. ap=0.056. bp=0.030.

Figure 2

Individual curves representing albuminuria (A) and GFR (B) in each patient during the study.

Sodium excretion, potassium excretion, or volume in 24-hour urine samples did not change significantly after LI-ESWT. Median creatinine clearance was 56.2 mL/min (IQR 36.5; 70.1) at baseline and was not significantly affected by LI-ESWT (p=0.165).

Median baseline systolic ambulatory blood pressure was 126 mmHg (IQR 119; 133) and median baseline diastolic ambulatory blood pressure was 70 mmHg (IQR 64; 79). The ambulatory blood pressure did not change through follow-up visits compared to baseline.

Adjustments made to the patients’ anti-hypertensive and anti-diabetic medical treatment during follow-up are outlined in .

Plasma Variables

There were no significant changes in hemoglobin, albumin, sodium, potassium, ionized calcium, phosphate, creatinine, or glycated hemoglobin throughout the study (Table 2). There was a significant increase in BUN (p=0.038). At baseline, median BUN was 10.4 mmol/L (IQR 8.8; 14.3) and increased at six-month follow-up visit where the median was 13.7 mmol/L (IQR 8.6; 15.8). In a post-hoc test, there was a significant increase in BUN from baseline to six-month follow-up visit (p=0.018) and from three-month follow-up visit to six-month follow-up visit (p=0.031).

Table 2

Outcome Variables

		Baseline	1 Month	3 Months	6 Months	p-valuea
51-chromium-EDTA clearance
Standard-GFR	mL/min/1.73m2	37.0 (27.3; 49.0)	-	36.0 (27.0; 46.8)	37.0 (24.0; 51.0)	0.351
Albuminuriab
Albumin (total)	mg/24hours	302 (78; 786)	253 (80; 1167)	295 (58; 907)	214 (100; 987)	0.801
24-hour urine
Volume	Ml	2332 (1822; 2541)	2437 (1626; 2703)	2318 (1647; 2838)	2180 (1678; 2763)	0.532
Creatinine clearance	mL/min	56.2 (36.5; 70.1)	51.8 (35.8; 74.9)	58.0 (38.9; 73.3)	58.4 (28.5; 73.4)	0.165
Sodium	mmol/24hours	189 (141; 214)	199 (148; 224)	170 (123; 243)	170 (115; 216)	0.341
Potassium	mmol/24hours	65 (49; 82)	65 (54; 90)	70 (48; 92)	65 (52; 87)	0.307
Ambulatory blood pressure
Systolic	mmHg	126 (119; 133)	124 (119; 138)	126 (119; 134)	123 (117; 137)	0.534
Diastolic	mmHg	70 (64; 79)	72 (63; 77)	71 (65; 79)	69 (65; 78)	0.918
Blood samples
Hemoglobin	mmol/L	8.2 (7.3; 8.7)	8.0 (7.3; 8.4)	8.2 (7.3; 8.5)	8.0 (7.5; 8.4)	0.967
Albumin	g/L	43 (41; 45)	43 (40; 45)	42 (40; 44)	42 (41; 44)	0.228
Sodium	mmol/L	138 (135; 141)	139 (136; 141)	137 (136; 140)	139 (137; 141)	0.081
Potassium	mmol/L	4.2 (3.9; 4.5)	4.5 (4.1; 4.6)	4.3 (4.1; 4.6)	4.4 (4.0; 4.7)	0.736
Ionised calcium	mmol/L	1.26 (1.20; 1.29)	1.25 (1.21; 1.27)	1.24 (1.21; 1.27)	1.25 (1.22; 1.29)	0.493
Phosphate	mmol/L	1.05 (0.93; 1.16)	1.08 (0.97; 1.20)	1.07 (0.93; 1.17)	1.07 (0.95; 1.17)	0.992
Creatinine	µmol/L	149 (128; 189)	154 (121; 201)	159 (121; 200)	168 (118; 199)	0.271
eGFR	mL/min/1.73m2	38 (31; 48)	39 (28; 48)	37 (28; 46)	34 (25; 47)	0.473
BUN	mmol/L	10.4 (8.8; 14.3)	11.8 (9.1; 14.3)	11.9 (8.6; 13.2)	13.7 (8.6; 15.8)	0.038c
Glycated hemoglobin	mmol/mol	61 (53; 75)	60 (55; 75)	61 (54; 71)	64 (55; 69)	0.756

Notes: Data are presented as median (25% quartile; 75% quartile). aFriedman test. bPatients with non-significant albuminuria are excluded (6 patients with <30 mg/24-hour at all visits). cUnadjusted post-hoc test showed significant difference between baseline BUN and 6 months BUN (p=0.018) and between 3 months BUN and 6 months BUN (p=0.031). Post-hoc test adjusted for multiple testing (Bonferroni method) showed no significant pair-wise differences between the visits.

NOx and VEGF Excretion

In spot urine samples, the concentration of NOx concentration increased numerically after LI-ESWT but not in a statistically significant way (Table 3). Median urine VEGF was 76.0 ng/mmol (36.3; 123.1) at baseline and decreased significantly to 54.9 ng/mmol (39.5; 101.7) at one-month follow-up (p=0.056). There were no further significant differences in urine VEGF excretion. Individual curves representing NOx and VEGF in each patient during the study are provided in Figure 3.

Figure 3

Individual curves representing VEGF (A), NOx (B) and TFF3 (C) in each patient during the study.

Markers of Kidney Injury

Median urine TFF3 increased significantly to 23.1 ng/mmol (12.2; 66.5) after the first treatment session compared to a baseline median value of 13.3 ng/mmol (8.6; 33.7) (p=0.030) (Table 3). However, at all other visits, there were no significant changes in TFF3 relative to baseline. KIM-1 and clusterin tended to decrease after the first treatment session compared to baseline but the results were not statistically significant. After the first treatment, median urine KIM-1 was 69.8 ng/mmol (47.0; 120.7) compared to 394 ng/mmol (62.2; 1150) at baseline (p>0.10). Median urine clusterin was 4699 ng/mmol (2780; 17,732) after the first treatment in comparison to 8137 ng/mmol (3131; 23,468) at baseline (p>0.10). Individual curves representing TFF3 in each patient during the study are provided in Figure 3.

Correlation Analyses Between Outcomes

There were significant correlations between the recorded variables with an overview provided in . Notably, the levels of NOx, calbindin, clusterin, KIM-1, osteoactivin, TFF3, and VEGF tended to change after LI-ESWT in a manner that depended on the baseline level. The kidney injury markers decreased in those patients that displayed high baseline level of these markers. The patients who had a low baseline level of injury markers tended to have an increase in these markers after LI-ESWT. NOx and VEGF tended to increase in the patients who had low baseline levels of NOx and VEGF but were reduced in the patients with high levels at baseline. These effects were evident in close relation to the treatment sessions ie first treatment, sixth treatment, and 1-month follow-up. However, the effect persisted at six-month follow-up for NOx and calbindin. Furthermore, after the first treatment session, the change in VEGF correlated positively with the change in NOx.

Discussion

The present study found no significant changes in GFR and albuminuria after LI-ESWT. Albuminuria decreased in half of the patients after LI-ESWT but with no overall significant decline. BUN increased at six-month follow-up compared to baseline but was stable after one month and three months. Plasma concentrations of creatinine, potassium, and phosphate and creatinine clearance were unaffected by LI-ESWT. In the present study, the side effects to LI-ESWT were comparable to our previous report.25 In summary, LI-ESWT is clinically and biochemically safe in human diabetic kidney disease.

To our knowledge, this study represents the first data on LI-ESWT in human kidney disease. A previous study in a pig model of kidney disease demonstrated that LI-ESWT improved renal microvascular density, tissue oxygenation, and GFR following ischemic kidney injury.26 Thus, LI-ESWT promoted a regenerative angiogenic response in kidneys with ischemic injury through a mechanism involving stimulation of focal adhesion kinase and beta 1-integrin that transmit the mechanical stimulus of LI-ESWT.26 In animals, VEGF increased after LI-ESWT in various types of renal disease26–28 including type-1 DKD.29 Furthermore, eNOS expression improved after LI-ESWT in animal models of acute ischemic renal disease26 and chronic renal disease.28 However, in hypertensive renal disease in rats, LI-ESWT did not improve VEGF or eNOS expression.30 Interestingly, recent animal data suggested that LI-ESWT increase the expression of stromal-derived cell factor-1 and promote homing of endothelial progenitor cells to injured renal tissue.31

In spot urine samples, we found no overall changes in NOx. VEGF was transiently reduced after one month. Previous studies show that NOx is increased immediately after shockwave lithotripsy (ESWL) in both plasma and urine.32 In rodents, ESWL leads to activation of the NO-cGMP pathway which may counteract renal vasoconstriction.33 In particular, ESWL causes renal vasoconstriction in humans,34 and we therefore speculate that the production of NOx could be secondary to transient renal ischemia induced by shockwaves. In the present study, we did not measure renal blood flow or resistive index during LI-ESWT to further investigate this mechanism.

Kidney injury markers in spot urine were not significantly affected by LI-ESWT except TFF3 which increased at the first treatment session. TFF3 is a peptide that plays a protective role for epithelial surfaces in the gastrointestinal tract but its function in the kidney is not fully clarified.35 In rodents, TFF3 decreased in urine and kidney tissue a few days following tubular injury whereas urinary levels of albumin, KIM-1, and clusterin increased.36,37 Seemingly, TFF3 changes in an opposite pattern compared to other kidney injury markers after acute tubular injury. However, in human chronic kidney disease, urinary levels of TFF3 are increased suggesting on-going epithelial repair.38 In the present study, the increase in TFF3 was short lasting (

In rats, LI-ESWT reduced serum levels of kidney injury markers neutrophil gelatinase-associated lipocalin (NGAL) and KIM-1 and renal tissue injury after renal reperfusion injury.39 In the present study, KIM-1 and clusterin decreased in the majority of patients after the first session of LI-ESWT but not overall statistically significantly. In animal studies, LI-ESWT reduced renal fibrosis following chronic proteinuric kidney disease28 and after renal ischemic injury or reperfusion injury.26,40 We did not include renal tissue data or circulating fibrosis biomarkers in the present report to investigate the potential of LI-ESWT to reduce tissue fibrosis. Osteoactivin is suggested to trigger upregulation of collagen and matrix metalloproteinase expression and induce renal interstitial fibrosis.41 However, we found no change in the urinary excretion of osteoactivin after LI-ESWT.

In a secondary correlation analysis, we found a remarkable association between the urinary level of NOx, VEGF, and kidney injury markers at baseline and the respective changes in these molecules during treatments and follow-up. Thus, there was a tendency towards an increase in NOx in urine after LI-ESWT in those patients who had a relatively low excretion of NOx at baseline. Apparently, with increasing baseline levels, the changes in the NOx, VEGF, and kidney injury markers decreased linearly after LI-ESWT. That also meant that NOx and VEGF tended to decrease in the patients who had a relatively high level at baseline. Interpreting these results, the patients with most extreme excretions of NOx, VEGF, and kidney injury markers regressed towards mean levels after LI-ESWT. In the present study, we found no explanation as to why this effect in the kidney was seen.

At baseline, we found that albuminuria was present almost exclusively in patients with relatively low levels of NOx and relatively high levels of VEGF, and that lower NOx or higher VEGF was associated with exponentially increasing albuminuria. In animals, VEGF is increased under the circumstances of DKD.42 Conversely, in some studies of human DKD, VEGF is reduced and VEGF antagonism lead to adverse renal outcomes.43 It is suggested that in DKD there is an impairment of the VEGF-NO axis where VEGF is uncoupled from its normal stimulation of NO and regulation of angiogenesis.44 The fact that NOx tended to increase after LI-ESWT in the patients who had a low level of NOx at baseline could potentially work as a protective factor against albuminuria. In the patients who had increasing VEGF during the treatment sessions and early follow-up, GFR tended to improve later after three and six months. It is possible that VEGF may be used in future studies to divide patients in response/non-response groups after LI-ESWT. However, in correlation analysis, we found no other clinical feature or biomarker that could be used to predict changes in GFR, albuminuria, or blood pressure. After the first session of LI-ESWT, VEGF and NOx acutely changed in the same direction within the patients as demonstrated in our secondary correlation analysis. However, at follow-up, there was no clear relationship between the change in NOx and the change in VEGF that could indicate a possible restoration of the balance between VEGF and NO.

Our study is limited in that no control group was implemented. Furthermore, the patients were followed for relatively short time (six months) which, in the absence of LI-ESWT, may be too short to record significant changes in GFR or albuminuria in patients with diabetic kidney disease. We did not count how many patients were screened for participation. It is possible that our study population is selective considering that the most fragile or comorbid patients might have declined participation due to the relatively intense study program. We detected no significant changes in GFR and albuminuria after LI-ESWT demonstrating that LI-ESWT is not harmful. In perspective, LI-ESWT can prevent loss of kidney function or reduce the rate of kidney functional decline, but a control group and longer-term follow-up is needed to evaluate such effects. Moreover, the interventions should likely be repeated in order to maintain the effect on long-term. In patients with DKD, small annual reductions in GFR is expected in both type-1 DM45 and type-2 DM.46 In the present study, we carefully monitored covariates that could bias GFR and albuminuria. There were no changes in ambulatory blood pressure or HbA1c during follow-up. Two patients discontinued their treatment with ACE-inhibitor early during follow-up possibly constituting a bias for renal functional outcomes. LI-ESWT elicited a number of positive effects in animal models of renal disease.26,28,29 However, in these studies, LI-ESWT was applied with lower energy at 0.09–0.13 mJ/mm2 compared to our study. Future clinical studies need focus on dose–response relationship of LI-ESWT. It is also likely that the effective dose of LI-ESWT energy received in the kidney might be variable based on different patients’ weight and soft tissue thickness. In futures studies, it would be useful to determine whether there is a need to individually adjust the energy level of LI-ESWT based on factors such as skin to kidney distance.

In conclusion, we report that LI-ESWT is clinically safe and does not adversely affect markers of kidney injury in patients with DKD. We found no change in primary renal functional outcomes, ie GFR and albuminuria. LI-ESWT had no overall effect on VEGF and NOx excretion in urine. An exploratory analysis indicated that NOx increased in patients who had low levels of NOx. VEGF temporarily increased after LI-ESWT in patients with low level of VEGF. Furthermore, an increase in VEGF after LI-ESWT was associated with improving GFR. We recommend that LI-ESWT is evaluated in a randomized, placebo-controlled trial.